Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

MPI – Scientific journal highlights study of the DRP tool in cisplatin treatment for patients with lung cancer

Regulatory

Medical Prognosis Institute publishes selected financial information for the period 1 July 2017 – 31 December 2017 due to the proposed merger between Medical Prognosis Institute and Oncology Venture

Regulatory

Proposed merger between Medical Prognosis Institute and Oncology Venture

Regulatory

MPI’s spinout Oncology Venture announces positive interim results from a Phase 1/2 DRP guided study of LiPlaCis in heavily pretreated breast cancer patients

Regulatory

MPI’s spinout Oncology Venture will execute license to multi TKI phase 3 compound

Non-Regulatory

Drug response prediction in high-risk multiple myeloma – prediction of melphalan and bortezomib response.

Non-Regulatory

Result of evaluation of DRP for TKI drug from Big Pharma available third week of January 2018

Non-Regulatory

MPI Announces registration of trademark for DRP

Regulatory

MPI – LiPlaCis Phase 2 Recruitment Ongoing in DRP Screened Breast Cancer Patients: Relevant Clinical Benefits in 3 out of 5 Treated Patients

Regulatory

MPI: MPI publishes Half-year Report for the first half of 2017

Non-Regulatory

MPI: DRP to be evaluated in 6 to 7 prospective studies

Non-Regulatory

MPI: 2X Oncology’s CEO, George O. Elston’s newsletter to shareholders

Non-Regulatory

MPI – Investor Analysis of Oncology Venture Sweden AB

Non-Regulatory

MPI: Artikel om MPI og Oncology Venture i Medwatch

Regulatory

MPI: OV to evaluate the potential of in-licensing a small molecule compound for development in cancer from a major Pharmaceutical company

Regulatory

MPI – Last day of trading in paid subscription shares

Regulatory

MPI: Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 – 2X-121

Regulatory

MPI raised SEK 10,3 million in rights issue

Non-Regulatory

Cancer response to OV’s LiPlaCis successfully predicted in early data by MPIs DRP technology

Regulatory

Medical Prognosis Institute A/S Announces Start of Subscription Period for Rights Issue